Search
Now showing items 11-20 of 22
Precision genomics for prostate cancer patient stratification
(Institute of Cancer Research (University Of London), 2020-10-31)
Introduction Several unmet needs currently persist in advanced prostate cancers. Despite recent discoveries, such as identification of deficient DNA repair pathways as a key driver of prostate tumour development, relatively ...
Phospho-proteomics and functional genomics for the characterisation of resistance mechanisms to agents targeting the EGFR, PI3K and MAPK pathways and their application in guiding drug combinations in colorectal cancer
(Institute of Cancer Research (University Of London), 2019-12-31)
KRAS mutant and RAS/BRAF wild type (RAS WT) colorectal cancer (CRC) cells respond differently to targeted agents, as exemplified by cetuximab, an anti-EGFR antibody, which is only effective in a proportion of patients with ...
Dynamic predictive joint models to characterise localised prostate cancer prognosis after radiotherapy
(Institute of Cancer Research (University Of London), 2023-09-19)
This thesis aims to develop and validate dynamic predictive joint models (JMs) to characterise the prognosis of patients with localised prostate cancer who are treated with moderately hypofractionated radiotherapy with ...
Identifying predictive and prognostic markers in localised oesophagogastric cancer
(Institute of Cancer Research (University Of London), 2022-11-23)
The survival of patients with localised oesophagogastric (OG) cancer is poor even with multimodality therapy and modern surgical techniques. The need to identify robust but easily-reproducible prognostic and predictive ...
Exploring tumour evolution through single-cell sequencing
(Institute of Cancer Research (University Of London), 2023-10-24)
Tumours are composed of heterogeneous populations of cells which, under the pressure of the host and
external treatments, evolve across time and space. Recent advances in next-generation sequencing
technologies have ...
Targeting DNA damage response in oesophagogastric cancers
(Institute of Cancer Research (University Of London), 2023-05-30)
A subset of patients with oesphophagogastric (OG) adenocarcinomas are characterised by homologous recombination repair deficiency (HRD), providing the rationale for poly (ADP-ribose) polymerase inhibitor (PARPi) therapy ...
The role of cancer-associated fibroblasts in altering signal transduction and drug resistance in KRAS mutated cancers
(Institute of Cancer Research (University Of London), 2023-01-04)
KRAS is commonly mutated in solid tumours but effective treatment is limited due to resistance. Cancer-associated fibroblasts (CAFs) are a key tumour microenvironment component but how it interacts with KRAS mutant-cancer ...
Utilising novel therapies in the treatment of gastrointestinal cancers
(Institute of Cancer Research (University Of London), 2023-05-04)
Background:
Gastrointestinal (GI) malignancies are common and frequently lethal diseases. For most, treatment options revolve around chemotherapy where efficacy beyond second line is negligible, and toxicity is high. Novel ...
ctDNA guided diagnosis and management of gastrointestinal cancers
(Institute of Cancer Research (University Of London), 2023-07-05)
Gastrointestinal (GI) cancers including pancreatic (PC), biliary tract (BTC) and colorectal cancers (CRC) rely on a tissue biopsy through invasive procedures such as endoscopies and colonoscopies. Timely diagnosis of these ...
Deciphering evolutionary trajectories in hereditary renal cell carcinomas
(Institute of Cancer Research (University Of London), 2024-01-16)
Establishing the limits of predictability in cancer evolution has significant implications for
precision medicine. Clear cell renal cell carcinoma (ccRCC) follows highly deterministic
evolutionary pattern with conserved ...